First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma

• Verfasst von: Stacchiotti, Silvia [VerfasserIn]
• Verfasst von: Van der Graaf, Winette T. A. [VerfasserIn]
• Verfasst von: Sanfilippo, Roberta G. [VerfasserIn]
• Verfasst von: Marreaud, Sandrine I. [VerfasserIn]
• Verfasst von: Van Houdt, Winan J. [VerfasserIn]
• Verfasst von: Judson, Ian R. [VerfasserIn]
• Verfasst von: Gronchi, Alessandro [VerfasserIn]
• Verfasst von: Gelderblom, Hans [VerfasserIn]
• Verfasst von: Litiere, Saskia [VerfasserIn]
• Verfasst von: Kasper, Bernd [VerfasserIn]
• Titel: First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma
• Titelzusatz: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis
• Verf.angabe: Silvia Stacchiotti, Winette T.A. Van der Graaf, Roberta G. Sanfilippo, Sandrine I. Marreaud, Winan J. Van Houdt, Ian R. Judson, Alessandro Gronchi, Hans Gelderblom, Saskia Litiere, and Bernd Kasper
• E-Jahr: 2022
• Jahr: 13 May 2022
• Umfang: 7 S.
• Fussnoten: Gesehen am 06.11.2023
• Titel Quelle: Enthalten in: Cancer
• Ort Quelle: New York, NY : Wiley-Liss, 1948
• Jahr Quelle: 2022
• Band/Heft Quelle: 128(2022), 15 vom: Aug., Seite 2932-2938
• ISSN Quelle: 1097-0142
• DOI: doi:10.1002/cncr.34264
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: anthracycline
• Sach-SW: chemotherapy
• Sach-SW: doxorubicin
• Sach-SW: epirubicin
• Sach-SW: ifosfamide
• Sach-SW: liposarcoma
• Sach-SW: sarcoma
• K10plus-PPN: 1869367596

Abstract

BACKGROUND No prospective trial with anthracycline-based chemotherapy has individually assessed response in a well-differentiated (WD)/dedifferentiated (DD) liposarcoma patient cohort. We conducted a retrospective analysis of first-line chemotherapy in liposarcoma of intra-abdominal origin (IA-LPS) in patients who had entered the European Organisation for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) trials. METHODS We searched for all adult patients treated with first-line chemotherapy for advanced IA-LPS in the EORTC STBSG phase 2 and 3 trials from 1978. Treatment was aggregated into 5 groups: anthracycline alone, ifosfamide alone, doxorubicin plus ifosfamide (D+IFO), doxorubicin/cyclophosphamide/vincristine/dacarbazine, and “other” (brostallicin, trabectedin). Response was assessed prospectively by Response Evaluation Criteria in Solid Tumors or World Health Organization criteria. Progression-free survival (PFS) and overall survival (OS) were computed by Kaplan-Meier method. RESULTS A total of 109 patients with IA-LPS from 13 trials were identified (104 evaluable for response). Overall, there were 10/109 (9.2%) responders: 3/48 (6.3%) in the anthracycline alone group, 2/15 (13%) in the ifosfamide alone group, and 4/18 (22%) in the D+IFO group. At the 10-month median follow-up (interquartile range, 6-24), the median OS was 19 months (95% CI, 15-21) and median PFS 4 months (95% CI, 3-6). D+IFO achieved a not statistically significant longer median PFS (12 months) and median OS (31 months) than observed with other regimens. Univariate/multivariate analysis did not identify prognostic factors. CONCLUSIONS Cytotoxic chemotherapy, in particular anthracycline alone, had marginal activity in advanced IA-LPS. Ifosfamide-containing regimens showed higher activity, although it was not statistically significant and in a small number of cases, with the combination of doxorubicin and ifosfamide appearing to be the more active regimen available in fit patients. This series provides a benchmark for future trials on new drugs in WD/DD liposarcoma.;